13-Mar-2026
Globe Newswire (Sat, 14-Mar 10:15 AM ET)
Senseonics Expands European Eversense Operations via Asset Agreements
TipRanks (Thu, 12-Mar 4:37 PM ET)
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Mon, 2-Mar 4:01 PM ET)
Sequel Med Tech and Senseonics Launch Transformative Combination of twiist and Eversense 365
Globe Newswire (Thu, 19-Feb 8:00 AM ET)
Globe Newswire (Thu, 29-Jan 4:01 PM ET)
Globe Newswire (Wed, 28-Jan 4:05 PM ET)
Globe Newswire (Mon, 12-Jan 8:00 AM ET)
Globe Newswire (Thu, 8-Jan 4:01 PM ET)
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.
Senseonics Holdings trades on the NASDAQ stock market under the symbol SENS.
As of March 13, 2026, SENS stock price climbed to $5.64 with 446,669 million shares trading.
SENS has a beta of 2.26, meaning it tends to be more sensitive to market movements. SENS has a correlation of 0.24 to the broad based SPY ETF.
SENS has a market cap of $230.44 million. This is considered a Small Cap stock.
Last quarter Senseonics Holdings reported $14 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $100,000 and missed earnings estimates by -$.03.
In the last 3 years, SENS traded as high as $28.00 and as low as $5.00.
The top ETF exchange traded funds that SENS belongs to (by Net Assets): VTI, VXF, SCHA, ITOT, SCHB.
SENS has underperformed the market in the last year with a price return of -50.2% while the SPY ETF gained +21.4%. SENS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.7% and -31.8%, respectively, while the SPY returned -2.6% and -3.5%, respectively.
SENS support price is $5.28 and resistance is $5.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SENS shares will trade within this expected range on the day.